AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
- 4.3k Downloads
Despite treatment with the current standard-of-care therapies, patients with newly diagnosed glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated activity in patients with recurrent GBM and phase 2 trials indicate that the combination of bevacizumab with standard-of-care therapy is feasible and active for patients with newly diagnosed GBM. Bevacizumab has been granted US approval for use as single-agent therapy for patients with progressive GBM following prior therapy, although it has not received approval for use in patients with GBM in Europe. Phase 3 studies have been initiated in patients with newly diagnosed GBM and are currently recruiting patients. We describe the protocol for the AVAglio phase 3 registration trial, which is designed to evaluate the efficacy and safety of combining bevacizumab with standard-of-care therapy in patients with newly diagnosed GBM.
Keywordsbevacizumab clinical trial glioblastoma multiforme phase 3
- 17.Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71:1372–1380.PubMedCrossRefGoogle Scholar
- 20.Gruber ML, Raza S, Gruber D, Narayana A. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progressionfree survival, overall survival, and toxicity. J Clin Oncol. 2009;27(Suppl):15s (abstract 2017).Google Scholar
- 21.Anon. A study of Avastin (bevacizumab) in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. Available at: http://clinicaltrials.gov/ct2/show/NCT00943826. Accessed July 14, 2010.
- 22.Chinot O, de La Motte Rouge T, Moore N, Zeaiter A. Addition of bevacizumab to the multi-modality standard care in patients with newly diagnosed glioblastoma: a phase III trial. Poster presented at: 34th ESMO Multidisciplinary Congress, September 20–24, 2009; Berlin, Germany.Google Scholar
- 26.Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr Neurol Neurosci Rep. In press.Google Scholar
- 27.Anon. Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma. Available at: http://clinicaltrials.gov/ct2/show/NCT00884741. Accessed July 14, 2010.